C-reactive protein and cardiovascular risk in the metabolic syndrome and type 2 diabetes: Controversy and challenge

Clinical Diabetes

Volumn 25, Issue 1, 2007, Pages 16-22

  Capuzzi, David M ^a   Freeman, Jeffrey S ^b  

^a LANKENAU HOSPITAL   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN; C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETANERCEPT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY RISK; DISEASE COURSE; DISEASE MARKER; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MACROPHAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PREDICTION; PROGNOSIS; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 33846992271     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.25.1.16     Document Type: Review

References (62)

1. Tillet WS, Francis T: Serological reaction in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 52:561-571, 1930
2. MacLeod CM, Avery OT: The occurrence during acute infections of a protein not normally present in the blood. II. Isolation and properties of the reactive protein. J Exp Med 73:183-191, 1943
3. Lofstrom G: Comparison between the reaction of acute phase serum with pneumococcus C-polysaccaride and with pneumococcus type 27. Br J Exp Pathol 25:21-26, 1944
4. Shrive AK, Metcalfe AM, Cartwright JR, Greenhough TJ: C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of Limulus SAP. J Mol Biol 290:997-1008, 1999
5. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106:1439-1441, 2002
6. Yeh ETH, Palusinski RP: C-reactive protein: the pawn has been promoted to queen. Curr Atheroscler Rep 5:101-105, 2003
7. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126, 1999
8. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105:1135-1143, 2002
9. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JMC: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 98:531-535, 2000
10. Armani A, Becker RC: The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease. Part II. Am Heart J 149:977-983, 2005
11. Verma S, Wang C-H, Li S-H, Dumont AS, Fedak PWM, Badiwala MV, Dhillon B, Weisel RD, Li R-K, Mickle DAG, Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106:913-919, 2002
12. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folson AR, Heiss G, Sharrett AR: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109:837-842, 2004
13. Crea F, Monaco C, Lanza GA, Maggi E, Ginnetti F, Cianflone D, Niccoli G, Cook T, Bellomo G, Kjekshus J: Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin Cardiol 25:461-466, 2002
14. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844, 1998
15. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565, 2002
16. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294:326-333, 2005
17. Stern MP: Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 44:369-374, 1995
18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
19. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767-1772, 2000
20. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843, 2000
21. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ: Metabolic syndrome and 10-year cardiovascular risk in the Hoorn Study. Circulation 112:666-673, 2005
22. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M: Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck Study. Diabetes Care 26:1251-1257, 2003
23. Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22:1971-1977, 1999
24. Festa A, D'Agostino R Jr, Howard G, Mykkänan L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42-47, 2000
25. Campos SP, Baumann H: Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 12:1789-1797, 1992
26. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448-1454, 2005
27. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016-2021, 2002
28. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391-397, 2003
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106:3143-3421, 2002
30. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, Ermini G, Savorani G, Zocchi D, Melchionda N: WHO and ATP III proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med 21:383-387, 2004
31. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237-252, 2003
32. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289-2304, 2005
33. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752, 2005
34. Hak AE, Stehouwer CDA, Bots ML, Polderman KH, Schalkwijk CG, Westendorp ICD, Hofman A, Witteman JCM: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical arteriosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19:1986-1991, 1999
35. Grundy SM: The metabolic syndrome still lives. Clin Chem 51:1352-1357, 2005
36. Ford ES: The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168:351-358, 2003
37. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
38. Festa A, Haffner SM: Inflammation and cardiovascular disease in patients with diabetes: lessons from the Diabetes Control and Complications Trial. Circulation 111:2414-2415, 2005
39. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108:1070-1077, 2003
40. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389, 2001
41. King DE, Mainous AG III, Buchanan TA, Pearson WS: C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 26:1535-1539, 2003
42. Thorand B, Löwel H, Schneider A, Kolb H, Meisinger C, Fröhlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg Cohort Study, 1984-1998. Arch Intern Med 163:93-99, 2003
43. Best LG, Zhang Y, Lee ET, Yeh J-L, Cowan L, Palmieri V, Roman M, Devereux RB, Fabsitz RR, Tracy RP, Robbins D, Davidson M, Ahmed A, Howard BV: C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 112:1289-1295, 2005
44. Tracy RP, Kuller LH: C-reactive protein, heart disease risk, and the popular media. Arch Intern Med 165:2058-2060, 2005
45. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91:1351-1357, 1993
46. Yue CC, Muller-Greven J, Dailey P, Lozanski G, Anderson V, Macintyre S: Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum. J Biol Chem 271:22245-22250, 1996
47. Ledue TB, Rifai N: Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 49:1258-1271, 2003
48. Miller M, Zhan M, Havas S: High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 165:2063-2068. 2005
49. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387-1397, 2004
50. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511, 2003
51. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, for the Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44:720-732, 2004
52. Caballero AE: Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11:1278-1289, 2003
53. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002
54. Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X: Peroxisome preliferator-activated receptor-γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metab Clin Exp 54:590-597, 2005
55. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti MM, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, on behalf of the PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289, 2005
56. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK: Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166:902-908, 2006
57. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P, for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352:29-38, 2005
58. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald D, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20-28, 2005
59. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
60. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J, for the ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158, 2003
61. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965, 2001
62. Ridker PM, on behalf of the JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 109:2292-2297, 2003